search

Active clinical trials for "Mucocutaneous Lymph Node Syndrome"

Results 21-30 of 50

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

Kawasaki Disease

This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.

Completed27 enrollment criteria

Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease

Kawasaki Disease

The purpose of this study is to evaluate the safety, efficacy and of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with kawasaki diseases.

Completed17 enrollment criteria

Different Doses of IVIG for Kawasaki Disease

Kawasaki Disease

The objective of this study is to investigate the effect of different doses of intravenous immunoglobulin (IVIG) (1g/kg once, 1g/kg twice, 2g/kg once) for Kawasaki disease (KD) in a multicentre, prospective,randomised trial.

Completed6 enrollment criteria

Trial of Pulse Steroid Therapy in Kawasaki Disease--Pediatric Heart Network

Cardiovascular DiseasesHeart Diseases2 more

The primary endpoint is coronary artery diameter, normalized for body surface area, 5 weeks after randomization. Secondary endpoints include duration of fever, CRP levels, and adverse events.

Completed12 enrollment criteria

KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)

Mucocutaneous Lymph Node Syndrome

Kawasaki disease (KD) is a self-limited illness that affects the heart blood vessels (coronary arteries) of infants and children and is now the most common cause of acquired heart disease in children. A mixture of proteins from human blood (Intravenous immunoglobulin, IVIG) is a treatment that reduces the rate of the major complication of the disease: a bulging of the wall of the coronary arteries called an aneurysm. However, 10-20% of children are resistant to this treatment and the fever returns. These children have the highest rates of aneurysm formation and thus should be treated aggressively. Unfortunately, there are no guidelines for the best secondary treatment for these resistant patients because the problem has never been adequately studied. Most physicians choose either a second infusion of IVIG or an engineered antibody called infliximab that inactivates a molecule that promotes inflammation. This trial will randomize (assign by chance like the flip of a coin) IVIG-resistant patients to receive either a second IVIG infusion or infliximab and the response to treatment will be compared to learn which treatment stops the fever the fastest. In addition, parents and caregivers will provide observations about their child's response to the different treatments.

Completed7 enrollment criteria

Genetic Determinants of Kawasaki Disease

Kawasaki DiseaseAtypical Kawasaki Disease

Kawasaki disease (KD) is an acute self-limited vasculitis of infancy and early childhood. Most patients recover without sequelae although the inflammatory process causes permanent damage to the coronary arteries in 20-25% of untreated children. An infectious aetiology is suspected, but the causative agent has not been identified. The investigators aim to identify the genes underlying both susceptibility to Kawasaki disease, and the development of coronary artery aneurysms.

Active10 enrollment criteria

Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease

Kawasaki Disease

The purpose of this study is to determine whether the addition of infliximab to standard primary therapy of intravenous immunoglobulin (IVIG) and high dose aspirin will reduce resistance to therapy in acute Kawasaki disease (KD).

Completed29 enrollment criteria

A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease...

Kawasaki Disease

Determine the predictive value of CARDIOLITE® rest and stress myocardial perfusion imaging (MPI) to define a pediatric population with Kawasaki Disease (KD) at high and low risk of developing cardiac events.

Completed4 enrollment criteria

Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in...

Kawasaki Disease

This study evaluates the efficacy of the addition of infliximab to conventional initial treatment (intravenous immunoglobulin [IVIG] plus aspirin) in early regression of coronary artery lesion in patients with Kawasaki disease (KD).

Withdrawn11 enrollment criteria

A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric...

Kawasaki Disease

The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.

Completed4 enrollment criteria

Need Help? Contact our team!


We'll reach out to this number within 24 hrs